Drug-eluting stents: from bench to bed

Area of Science:

• Cardiology
• Interventional Cardiology
• Biomedical Engineering

Background:

• Percutaneous coronary intervention (PCI) revolutionized cardiac care with stent introduction in 1987.
• Stents initially addressed vessel closure during PCI, reducing the need for coronary artery bypass grafting (CABG).
• Stenting reduced restenosis rates from 30-40% with balloon angioplasty to 15-20%.

Purpose of the Study:

• To review advancements in drug-eluting stent (DES) technology.
• To discuss strategies for drug selection and stent design for optimal neointimal proliferation reduction.
• To evaluate preclinical and clinical data on DES efficacy and limitations.

Main Methods:

• Review of scientific literature on stent technology and drug-eluting coatings.
• Analysis of intravascular ultrasound (IVUS) studies demonstrating stent mechanisms.
• Synthesis of preclinical and clinical trial data for drug-eluting stents.

Main Results:

• Stenting has become the preferred method for over 80% of PCI procedures.
• Drug-eluting stents further reduce restenosis compared to bare-metal stents.
• Intravascular ultrasound studies confirmed stents mitigate elastic recoil and vascular remodeling.

Conclusions:

• Drug-eluting stents represent a major advancement in PCI, offering improved patient outcomes.
• Optimized drug selection and stent design are crucial for maximizing DES benefits.
• Ongoing research continues to refine DES technology, addressing its limitations and expanding its potential.